




PRISMAP (+) IN A NUTSHELL



T. Stora – CERN – Final Conference – Warsaw – 18-21 Nov 2025

We provide innovative radionuclides as active ingredients to promote research in the field

ERVI European Radioisotope Valley Initiative and **PRISMAP** is identified as strategic in Europe

<https://www.consilium.europa.eu/en/press/press-releases/2024/06/17/radioisotopes-for-medical-use-council-approves-conclusions/>




1958	1 January The Council is born The first meeting of the Council of the EEC takes place under the chairmanship of the Belgian foreign affairs minister.
1993	1 November Maastricht Treaty The Maastricht Treaty sees the creation of new policy areas such as common foreign and security policy and justice and home affairs.
2009	1 December The Lisbon Treaty The use of qualified majority voting for decision-making within the Council is extended under the Lisbon Treaty.

It all started there

■ From its preparation...

Integrating European Infrastructures for Starting Communities:
Physical mass separation to foster a new research era with emerging medical isotopes

INFRAIA SEPA-MEDISO




TOWARDS INTEGRATING EUROPEAN INFRASTRUCTURES FOR STARTING COMMUNITIES:
PHYSICAL MASS SEPARATION TO FOSTER A NEW RESEARCH ERA WITH EMERGING MEDICAL ISOTOPES



... to its start during COVID times

Europe Stays in Lockdown Mode

European countries by second-wave COVID-19 lockdown measures imposed*




* As of March 22, 2021

Restaurants closed: Austria, France, Luxembourg, Belgium, Croatia, Switzerland, parts of Finland. Business curfews in Spain, Italy, Portugal, Belgium, Kosovo, Serbia, Moldova, Ukraine and Bulgaria

PRISMAP

The EUROPEAN MEDICAL ISOTOPE PROGRAMME



Kick-Off meeting


Online, 15-17 June 2021



Our objectives

- Provide access to new radionuclides and new purity grades for medical research:
portfolio evolved, helpdesk, 17 over 28 radionuclides offered
- Create a common entry port and web interface for the starting research community
Please visit us at prismap.eu
- Enhance clarity and regulatory procedures to promote research with radiopharmaceuticals
EMA has identified PRISMAP as a stakeholder – Also look at our Zenodo platform
- Unlock the biomedical research through better data on radionuclides
A number of new nuclear data
- Ensure the long-term sustainability of PRISMAP
PRISMAP + under evaluation


PRISMAP supply chain (2020-2025)



An access platform with leading institutes in the supply chain for European biomedical researchers

From Call 1


to Call 5



<https://www.prismap.eu/access>

Access go our biomedical facilities


- Our medical facilities:
<https://www.prismap.eu/radionuclides/medical-facilities/>



The PRISMAP medical facilities offer access for the selected users of PRISMAP who request to be hosted in key facilities equipped for preclinical and clinical studies and located within suitable transport range of the radionuclide production facilities.









Dispatch of (many, many, many...) radionuclides across (many, many, many,...) projects and Europe (and beyond)



Projects selected in 5 subsequent calls for projects

User Selection Panel

Thierry Stora CERN - coord	Francesco Cicone Magna Graecia Univ Catanzaro - Nucl Medicine
Charlotte Duchemin CERN – techn manager	Sandra Heskamp Radboud Univ Med Centre – Nucl imaging and Therapy
Ferid Haddad ARRONAX - access	Cornelia Hoehr Univ Victoria, TRIUMF – Life science dept head
Ulli Köster ILL - production	Paul Lecoq Metacystal SA – head physics div. EURASC
David Viertl CHUV – medical app	Kristoff Muylle Vrije univ Brussels – former pres EANM
Kirsten Leufgen Sciprom – coord	Katherine Vallis Univ. Oxford – prof Radiotherapeutics



Biomedical translation in PRISMAP

2 (+1) projects aim at performing clinical trials
(first-in-human and phase-1/pilot)

P4

Towards ^{161}Tb -PSMA cell targeting
treatment of prostate cancer
biochemical recurrence: Comparison
with ^{177}Lu -PSMA

Tb-161

Dr. M. Kirienko

Italy

IMPD filed

P31

$^{203}\text{Tl}/^{212}\text{Pb}$ -mcp-D-PSMA for an
improved tumor therapy: Preclinical
evaluation, automatisation and
translation to clinical application

Pb-212/Pb-203

Dr. M. Pretze

Germany

Compassionnate care

P14

Zebrafish embryo as a novel model to evaluate the efficacy
of short range emitters used for targeted radionuclide therapy

Prof. C. Morgat

France

*Translation
outside of PRISMAP*

Feedback of projects


“The application process was smooth”

“Our experience with PRISMAP services has been exceptionally positive”

“The interest of this kind of project is the collaboration opportunities this can lead”

“Thanks to the excellent communication and flexibility demonstrated by all involved partners, minor issues were effectively addressed”

“The materials provided were of excellent quality, which underlines the uniqueness of the PRISMAP initiative”



Top Rated Oral Presentations @ EANM’25 congress in:
Combination Therapy - Shaping the Future of TRT
Innovations in Translational Oncology
Improving Radionuclide Production for Tracer Development

***Congrat’s to our users !
and our PRISMAP R&D institutes !***

Warsaw - final conference – 18-21Nov2025

Users feedback

“Deliveries were always on schedule”

“Optimal characteristics such as elevated purity and specific activity”

“PRISMAP provided us with the opportunity to use an innovative radioisotope with unique characteristics for theranostic applications”

“The communication was excellent”

“Great opportunity to establish scientific relationships with like-minded researchers and offers access to unique infrastructures”

“The application process was straightforward, and logistical aspects were handled professionally”

“Communication with PRISMAP was consistently clear and timely throughout the project, particularly regarding radionuclide delivery coordination”

“The team demonstrated excellent responsiveness and provided comprehensive support from initiation to completion”

“The application process was smooth”

“Our experience with PRISMAP services has been exceptionally positive”

“The interest of this kind of project is the collaboration opportunities this can lead”

“Logistics for delivery were well-organized, and all shipments arrived on time”

“Thank you for the outstanding service”

“We appreciate the professionalism and efficiency demonstrated throughout the process”

“Thanks to the excellent communication and flexibility demonstrated by all involved partners, minor issues were effectively addressed”

“We are grateful to PRISMAP and to all our interlocutors for their kindness and dedication”

“The materials provided were of excellent quality, which underlines the uniqueness of the PRISMAP initiative”

A non-exhaustive pot-pourri of our outcomes



10th International Symposium

on the Physical, Molecular, Cellular and Medical Aspects of Auger Electron Processes

September 6-8, 2023

Institut de Recherche en Cancérologie de Montpellier - France



Radionuclide Theranostics for the Management of Cancer
Gordon Research Conference





36th
Annual Congress of the
European Association of Nuclear Medicine

VIENNA

SEPTEMBER 9 – 13, 2023

eanm23.eanm.org

Decristoforo et al. *EJNMMI Radiopharmacy and Chemistry* (2025) 10:42
<https://doi.org/10.1186/s41181-025-00369-0>

EJNMMI Radiopharmacy
and Chemistry

POSITION PAPER

Open Access

To be GMP or not to be – a radionuclide's question

Clemens Decristoforo^{1*}, Renata Mikolajczak², Clive Naidoo³, Suzanne Lapi⁴, Ferid Haddad⁵,
David Emmanuel Schmid⁶, Lurdes Gano⁷, Ulli Köster⁸ and Thierry Stora⁹



The magic PRISMAP cocktail






Medical Radionuclides



PRISMAP
RADIOLANTHANIDES
WORKSHOP

3-5 September 2024



INTERNATIONAL SYMPOSIUM
ON TRENDS IN RADIOPHARMACEUTICALS
#ISTR2023
IAEA Headquarters, Austria
17 – 21 April 2023



European
Medical
Radionuclides
Programme

Opportunities to Foster Research with
Radiopharmaceuticals in Europe and Beyond
Thierry Stora, CERN





RADIOLANTHANIDE
SUMMER SCHOOL






T. Stora "View" > "Header and Footer" to change (in a nutshell)

Warsaw - final conference – 18-21 Nov 2025



From PRISMAP to PRISMAP+, furthering the European medical radionuclide programme (submitted for selection ->2029?)



Medical-radionuclides.eu and beyond : the long term for European biomedical research in Europe?

www.medical-radionuclides.eu



www.prismap.eu/news/

Final PRISMAP conference in
Warsaw



The way to cross the valley of death



Prof Dave Townsend –
co-inventor of PET-CT
visiting 



ONBOARD FOR THE EUROPEAN MEDICAL RADIONUCLIDE PROGRAMME !

[HTTPS://WWW.PRISMAP.EU/NEWS/](https://www.prismap.eu/news/)



[WWW.PRISMAP.EU](https://www.prismap.eu)



PRISMAP PROJECT



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101008571 (PRISMAP).